The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $8.98 billion in 2023 to $9.79 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The increase observed in the historical period can be attributed to the utilization of biosimilars in rare disease treatment, the globalization of clinical trials, healthcare reimbursement policies, designations of orphan drugs, and advancements in genetic research.
The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to improved diagnostic tools, advancements in precision medicine, the development of patient-centric drug development approaches, the integration of real-world evidence, the use of telemedicine for patient support, and a shift towards personalized therapies. Noteworthy trends expected during the forecast period include technological innovations, the application of artificial intelligence in drug discovery, the implementation of blockchain for data security, and the utilization of machine learning in drug discovery.
The anticipated growth of the rare neurological disease treatment market is expected to be driven by the prevalence of rare neurological diseases. These conditions, characterized by low prevalence, encompass disorders such as Huntington's disease, amyotrophic lateral sclerosis (ALS), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves employing diverse approaches to manage symptoms, slow disease progression, and enhance the quality of life for affected individuals. For example, as reported in January 2023 by BioMed Central Ltd., the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is a significant driver for the growth of the rare neurological disease treatment market.
The anticipated rise in healthcare expenditures is poised to fuel the growth of the rare neurological disease treatment market. Healthcare expenditures encompass all costs related to providing health services and focus on health-related activities. Increased spending in healthcare supports research, development, specialized care access, and awareness crucial for advancing treatments and support for rare neurological diseases. In December 2022, according to the Centers for Medicare & Medicaid Services, spending on healthcare in the United States increased by 2.7 percent to $12,914 per person in 2021, totaling $4.3 trillion. Healthcare spending accounted for 18.3 percent of the country's GDP. Hence, the surge in healthcare expenditures is contributing to the growth of the rare neurological disease treatment market.
A noteworthy trend gaining traction in the rare neurological disease treatment market is the development of orphan pharmaceuticals. Key companies in the sector are directing their efforts towards creating innovative and specialized treatments to solidify their market positions. For instance, in April 2023, French orphan drug development company Orphalan SA introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and exhibited tolerance to D-penicillamine. This drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.
Major players in the rare neurological disease treatment market are placing a strong emphasis on product innovation, including rare disease drug development solutions, to advance therapeutic options and enhance the quality of life for patients affected by rare neurological diseases. Developing treatments for rare neurological diseases necessitates targeted research into specific disease mechanisms and the exploration of innovative therapeutic approaches, such as gene therapies or personalized medicine, to address the complex nature of these conditions. For instance, in February 2023, US-based pharmaceutical company Reata Pharmaceuticals Inc. received approval from the United States Food and Drug Administration (USFDA) for Skyclarys, a drug designed to treat Friedreich’s ataxia, a rare neurological disease. Skyclarys represents an experimental medication addressing unmet needs in treating rare neurological conditions by targeting intricate disease mechanisms. It is undergoing rigorous clinical evaluation for its efficacy and safety profiles.
In August 2021 US-based pharmaceutical company Harmony Biosciences acquired HBS-102, an MCHR1 antagonist, from ConSynance Therapeutics Inc. for $3.5 million. This acquisition aims to enhance Harmony Biosciences' position as a leading company in treating rare neurological diseases. The addition of HBS-102 to Harmony Biosciences' pipeline signifies a crucial expansion beyond its flagship product, WAKIX, providing a potential treatment option for narcolepsy, a rare disease. ConSynance Therapeutics Inc. is a US-based company focused on developing innovative therapeutics for various conditions, including rare neurological disorders.
Major companies operating in the rare neurological disease treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.
North America was the largest region in the rare neurological disease’s treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare neurological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of treatment for rare neurological diseases involve drugs, including biologics and small molecules. Biologics, derived from living organisms such as proteins, antibodies, or nucleic acids, play a crucial role in treating rare neurological diseases. Examples include enzyme replacement therapies for lysosomal storage disorders and monoclonal antibodies for immune-mediated neurological disorders. Various therapies, such as cognitive behavioral therapy, interpersonal psychotherapy, and cyberknife, are administered through oral and injectable modes to address specific conditions such as Aicardi syndrome, Aicardi Goutières syndrome, reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Creutzfeldt-Jakob disease, agnosia, and others. Medications are distributed through channels including hospitals, retail pharmacies, drug stores, and online pharmacies.
The rare neurological diseases treatment market research report is one of a series of new reports that provides rare neurological diseases treatment market statistics, including the rare neurological diseases treatment industry's global market size, regional shares, competitors with a rare neurological diseases treatment market share, detailed rare neurological diseases treatment market segments, rare neurological diseases treatment market trends and opportunities, and any further data you may need to thrive in the rare neurological diseases treatment industry. This rare neurological diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The rare neurological disease treatment market consists of revenues earned by entities by providing supportive care services and neurodegenerative research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare neurological disease treatment market also includes sales of anticonvulsants, antidepressants, and beta blockers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $13.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to improved diagnostic tools, advancements in precision medicine, the development of patient-centric drug development approaches, the integration of real-world evidence, the use of telemedicine for patient support, and a shift towards personalized therapies. Noteworthy trends expected during the forecast period include technological innovations, the application of artificial intelligence in drug discovery, the implementation of blockchain for data security, and the utilization of machine learning in drug discovery.
The anticipated growth of the rare neurological disease treatment market is expected to be driven by the prevalence of rare neurological diseases. These conditions, characterized by low prevalence, encompass disorders such as Huntington's disease, amyotrophic lateral sclerosis (ALS), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves employing diverse approaches to manage symptoms, slow disease progression, and enhance the quality of life for affected individuals. For example, as reported in January 2023 by BioMed Central Ltd., the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is a significant driver for the growth of the rare neurological disease treatment market.
The anticipated rise in healthcare expenditures is poised to fuel the growth of the rare neurological disease treatment market. Healthcare expenditures encompass all costs related to providing health services and focus on health-related activities. Increased spending in healthcare supports research, development, specialized care access, and awareness crucial for advancing treatments and support for rare neurological diseases. In December 2022, according to the Centers for Medicare & Medicaid Services, spending on healthcare in the United States increased by 2.7 percent to $12,914 per person in 2021, totaling $4.3 trillion. Healthcare spending accounted for 18.3 percent of the country's GDP. Hence, the surge in healthcare expenditures is contributing to the growth of the rare neurological disease treatment market.
A noteworthy trend gaining traction in the rare neurological disease treatment market is the development of orphan pharmaceuticals. Key companies in the sector are directing their efforts towards creating innovative and specialized treatments to solidify their market positions. For instance, in April 2023, French orphan drug development company Orphalan SA introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and exhibited tolerance to D-penicillamine. This drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.
Major players in the rare neurological disease treatment market are placing a strong emphasis on product innovation, including rare disease drug development solutions, to advance therapeutic options and enhance the quality of life for patients affected by rare neurological diseases. Developing treatments for rare neurological diseases necessitates targeted research into specific disease mechanisms and the exploration of innovative therapeutic approaches, such as gene therapies or personalized medicine, to address the complex nature of these conditions. For instance, in February 2023, US-based pharmaceutical company Reata Pharmaceuticals Inc. received approval from the United States Food and Drug Administration (USFDA) for Skyclarys, a drug designed to treat Friedreich’s ataxia, a rare neurological disease. Skyclarys represents an experimental medication addressing unmet needs in treating rare neurological conditions by targeting intricate disease mechanisms. It is undergoing rigorous clinical evaluation for its efficacy and safety profiles.
In August 2021 US-based pharmaceutical company Harmony Biosciences acquired HBS-102, an MCHR1 antagonist, from ConSynance Therapeutics Inc. for $3.5 million. This acquisition aims to enhance Harmony Biosciences' position as a leading company in treating rare neurological diseases. The addition of HBS-102 to Harmony Biosciences' pipeline signifies a crucial expansion beyond its flagship product, WAKIX, providing a potential treatment option for narcolepsy, a rare disease. ConSynance Therapeutics Inc. is a US-based company focused on developing innovative therapeutics for various conditions, including rare neurological disorders.
Major companies operating in the rare neurological disease treatment market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.
North America was the largest region in the rare neurological disease’s treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare neurological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary types of treatment for rare neurological diseases involve drugs, including biologics and small molecules. Biologics, derived from living organisms such as proteins, antibodies, or nucleic acids, play a crucial role in treating rare neurological diseases. Examples include enzyme replacement therapies for lysosomal storage disorders and monoclonal antibodies for immune-mediated neurological disorders. Various therapies, such as cognitive behavioral therapy, interpersonal psychotherapy, and cyberknife, are administered through oral and injectable modes to address specific conditions such as Aicardi syndrome, Aicardi Goutières syndrome, reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Creutzfeldt-Jakob disease, agnosia, and others. Medications are distributed through channels including hospitals, retail pharmacies, drug stores, and online pharmacies.
The rare neurological diseases treatment market research report is one of a series of new reports that provides rare neurological diseases treatment market statistics, including the rare neurological diseases treatment industry's global market size, regional shares, competitors with a rare neurological diseases treatment market share, detailed rare neurological diseases treatment market segments, rare neurological diseases treatment market trends and opportunities, and any further data you may need to thrive in the rare neurological diseases treatment industry. This rare neurological diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The rare neurological disease treatment market consists of revenues earned by entities by providing supportive care services and neurodegenerative research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare neurological disease treatment market also includes sales of anticonvulsants, antidepressants, and beta blockers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Rare Neurological Disease Treatment Market Characteristics3. Rare Neurological Disease Treatment Market Trends and Strategies32. Global Rare Neurological Disease Treatment Market Competitive Benchmarking33. Global Rare Neurological Disease Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Rare Neurological Disease Treatment Market
4. Rare Neurological Disease Treatment Market - Macro Economic Scenario
5. Global Rare Neurological Disease Treatment Market Size and Growth
6. Rare Neurological Disease Treatment Market Segmentation
7. Rare Neurological Disease Treatment Market Regional and Country Analysis
8. Asia-Pacific Rare Neurological Disease Treatment Market
9. China Rare Neurological Disease Treatment Market
10. India Rare Neurological Disease Treatment Market
11. Japan Rare Neurological Disease Treatment Market
12. Australia Rare Neurological Disease Treatment Market
13. Indonesia Rare Neurological Disease Treatment Market
14. South Korea Rare Neurological Disease Treatment Market
15. Western Europe Rare Neurological Disease Treatment Market
16. UK Rare Neurological Disease Treatment Market
17. Germany Rare Neurological Disease Treatment Market
18. France Rare Neurological Disease Treatment Market
19. Italy Rare Neurological Disease Treatment Market
20. Spain Rare Neurological Disease Treatment Market
21. Eastern Europe Rare Neurological Disease Treatment Market
22. Russia Rare Neurological Disease Treatment Market
23. North America Rare Neurological Disease Treatment Market
24. USA Rare Neurological Disease Treatment Market
25. Canada Rare Neurological Disease Treatment Market
26. South America Rare Neurological Disease Treatment Market
27. Brazil Rare Neurological Disease Treatment Market
28. Middle East Rare Neurological Disease Treatment Market
29. Africa Rare Neurological Disease Treatment Market
30. Rare Neurological Disease Treatment Market Competitive Landscape and Company Profiles
31. Rare Neurological Disease Treatment Market Other Major and Innovative Companies
35. Rare Neurological Disease Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Rare Neurological Disease Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rare neurological disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rare neurological disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug Type: Biologics; Small Molecules
2) By Therapy: Cognitive Behavioral Therapy; Interpersonal Psychotherapy; Cyberknife; Other Therapies
3) By Mode Of Administration: Oral; Injectable; Other Modes Of Administration
4) By Disorders: Aicardi Syndrome; Aicardi-Goutières Syndrome; Reflex Sympathetic Dystrophy Syndrome; Battaglia-Neri Syndrome; Creutzfeldt Jakob Disease; Agnosia; Other Disorders
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies and Drug Store; Online Pharmacies
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi-Aventis SA
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Medtronic PLC
- Teva Pharmaceutical Industries Ltd.
- CSL Limited
- Biogen Inc.
- UCB S.A.
- Eisai Co. Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Jazz Pharmaceuticals PLC
- Mitsubishi Tanabe Pharma Corporation
- Neurocrine Biosciences Inc.
- Kedrion Biopharma Inc.
- Merz Pharma GmbH & Co. KGaA
- Harmony Biosciences Holdings Inc.
- Amicus Therapeutics Inc.
- Revance Therapeutics Inc.
- Aquestive Therapeutics Inc.
- US WorldMeds LLC (Solstice Neurosciences LLC)
- Stoke Therapeutics Inc.
- Retrotope Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 9.79 Billion |
| Forecasted Market Value ( USD | $ 13.41 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
